High-dose hydroxyurea with differentiating agents for treating ultra-high-risk acute promyelocytic leukemia in resource-challenged settings

Acta Oncol. 2022 Dec;61(12):1512-1514. doi: 10.1080/0284186X.2022.2162347. Epub 2022 Dec 29.

Authors

Charanpreet Singh¹, Sarthak Wadhera¹, Uday Yanamandra¹, Parathan Karunakaran¹, Nishant Jindal¹, Saloni Rani Kumar¹, Neha Saini¹, Aditya Jandial¹, Arihant Jain¹, Chandan Das¹, Gaurav Prakash¹, Alka Khadwal¹, Shano Naseem², Reena Das², Neelam Varma², Subhash Varma¹, Pankaj Malhotra¹, Deepesh Lad¹

Affiliations

¹ Department of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
² Department of Hematology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

PMID: 36579788
DOI: 10.1080/0284186X.2022.2162347

No abstract available

MeSH terms

Antineoplastic Agents* / therapeutic use
Humans
Hydroxyurea / therapeutic use
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Promyelocytic, Acute* / drug therapy

Substances

Hydroxyurea
Antineoplastic Agents